Vasogen Inc.

2505 Meadowvale Boulevard
Mississauga, L5N 5S2

Phone: (905) 817-2000
Fax: (905) 569-9231
Stock symbol: VSGN; VAS


Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company’s lead product, the Celacade™ technology, is designed to activate the immune response to apoptosis — an important physiological process that regulates inflammation. Celacade™ is in late-stage development for the treatment of chronic heart failure and has received European regulatory approval under the CE Mark for this indication. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders and is preparing to advance VP025, the lead drug candidate from this new class, into phase II development.